Beranda › Kanker Payudara Triple-Negatif › Pennsylvania › Philadelphia
Uji klinis Kanker Payudara Triple-Negatif di Philadelphia, PA
13 studi untuk Kanker Payudara Triple-Negatif mencari peserta di lokasi sekitar Philadelphia (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Menerima pesertaFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Menerima pesertaFase 1
- Sidney Kimmell Cancer Center - Jefferson Health, Philadelphia
Study of AVZO-021 in Patients With Advanced Solid Tumors
Menerima pesertaFase 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Menerima pesertaFase 3
- Sidney Kimmel Cancer Center at Jefferson ( Site 0049), Philadelphia
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Menerima pesertaFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Menerima pesertaFase 3
- University of Pennsylvania Abramson Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mi jauhnya
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Menerima pesertaFase 1
- Normunity Investigational Site, Philadelphia
- Normunity Investigational Site, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Menerima pesertaFase 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Menerima pesertaFase 2
- University of Pennsylvania (U Penn), Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Menerima pesertaFase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Menerima pesertaFase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
Menerima peserta
- Thomas Jefferson University Hospital, Philadelphia
Role of the Immune Environment in Response to Therapy in Breast Cancer
Menerima pesertaStudi observasional
- Abramson Cancer Center, Philadelphia
Uji klinis Kanker Payudara Triple-Negatif di kota lain
- Houston, TX42 studi
- New York City, NY31 studi
- Nashville, TN28 studi
- Los Angeles, CA27 studi
- Boston, MA26 studi
- San Antonio, TX23 studi
- St. Louis, MO21 studi
- Arlington, VA20 studi
- Atlanta, GA20 studi
- Dallas, TX18 studi
- Chicago, IL16 studi
- Columbus, OH16 studi
Studi lain di Philadelphia
- Kanker (semua jenis)59 studi
- Kanker Payudara56 studi
- Kanker Paru Non-Sel Kecil51 studi
- Kanker Metastatik46 studi
- Kanker Prostat44 studi
- Kanker Kolorektal44 studi
- Kanker Ovarium44 studi
- Kanker Paru36 studi
- Leukemia Mieloid Akut34 studi
- Gagal Jantung31 studi
- Kanker Endometrium28 studi
- Depresi26 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.